ArticleBiomaterials2013
Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction.
Article in Biomaterials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 76 citations in OpenAlex.
- Targeted delivery of peptide functionalized nanoparticles for ameliorating myocardial infarction.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Review
- Emerging dendrimer-based RNA delivery strategies.Nanomedicine (London, England) · 2025Review
- A Susceptible Cell-Selective Delivery (SCSD) of mRNA-Encoded Cas13d Against Influenza Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Using nanotechnology for the diagnosis and treatment of coronary artery disease: a narrative review.The British journal of cardiology · 2025Article
- Review
- Endothelial Brg1 fine-tunes Notch signaling during zebrafish heart regeneration.NPJ Regenerative medicine · 2023Article
- Nanoparticles Targeting the Molecular Pathways of Heart Remodeling and Regeneration.Pharmaceutics · 2022Review
- Polymeric nanoparticles in the diagnosis and treatment of myocardial infarction: Challenges and future prospects.Materials today. Bio · 2022Review
- Nanotechnology in cardiac stem cell therapy: cell modulation, imaging and gene delivery.RSC advances · 2021Review
- Non-Viral Gene Delivery Systems for Treatment of Myocardial Infarction: Targeting Strategies and Cardiac Cell Modulation.Pharmaceutics · 2021Review
- Albumin Nanoparticle Formulation for Heart-Targeted Drug Delivery: In Vivo Assessment of Congestive Heart Failure.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Poly (Lactic-Polymers · 2020Article
- Applications and Limitations of Dendrimers in Biomedicine.Molecules (Basel, Switzerland) · 2020Review
- Dendrimers: Amazing Platforms for Bioactive Molecule Delivery Systems.Materials (Basel, Switzerland) · 2020Review
- Dendrimers Show Promise for siRNA and microRNA Therapeutics.Pharmaceutics · 2018Review
- Nanoparticle-mediated siRNA Gene-silencing in Adult Zebrafish Heart.Journal of visualized experiments : JoVE · 2018Article
- Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases.International journal of nanomedicine · 2018Review
- Chromatin-remodelling factor Brg1 regulates myocardial proliferation and regeneration in zebrafish.Nature communications · 2016Article
- Anti-inflammatory Nanoparticle for Prevention of Atherosclerotic Vascular Diseases.Journal of atherosclerosis and thrombosis · 2016Review
- Nanotechnology in diagnosis and treatment of coronary artery disease.Nanomedicine (London, England) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Cardiovascular disease (CVD) is the leading cause of death throughout the world and much pathology is associated with upregulation of inflammatory genes. Gene silencing using RNA interference is a powerful tool in regulating gene expression, but its application in CVDs has been prevented by the lack of efficient delivery systems. We report here the development of tadpole dendrimeric materials for siRNA delivery in a rat ischemia-reperfusion (IR) model. Angiotensin II (Ang II) type 1 receptor (AT1R), the major receptor that mediates most adverse effects of Ang II, was chosen to be the silencing targeting. Among the three tadpole dendrimers synthesized, the oligo-arginine conjugated dendrimer loaded with siRNA demonstrated effective down-regulation in AT1R expression in cardiomyocytes in vitro. When the dendrimeric material was applied in vivo, the siRNA delivery prevented the increase in AT1R levels and significantly improved cardiac function recovery compared to saline injection or empty dendrimer treated groups after IR injury. These experiments demonstrate a potential treatment for dysfunction caused by IR injury and may represent an alternative to AT1R blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.